NCT04867369

Pecs II Block Versus Surgeon Infiltration for Open Subpectoral Biceps Tenodesis

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 160 (actual)
• Sponsor: NYU Langone Health · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

A phase IV, randomized, single-blind, single-center study measuring the effects of Pecs II block with 0.25% bupivacaine versus surgeon infiltration with 0.25% bupivacaine on postoperative pain control and opioid utilization in participants who undergo open subpectoral tenodesis.

Conditions

• Tendonitis

Interventions

Type	Name	Description
DRUG	Bupivacaine 20mL 0.5%	Interscalene nerve block with 20 mL 0.5% bupivacaine.
DRUG	Bupivacaine 20mL 0.25%	Pecs II fascial plane block with 20 mL 0.25% bupivacaine.
DRUG	Bupivacaine up to 15mL 0.25%	Local infiltration of 0.25% bupivacaine by the surgeon, up to 15 mL.

Timeline

• Start date: 2021-07-14
• Primary completion: 2023-11-08
• Completion: 2023-11-11
• First posted: 2021-04-30
• Last updated: 2024-12-13
• Results posted: 2024-12-13

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study